
For American Pharmacists Month, see how recent instances of conflicting medical advice show the importance of pharmacists as trustworthy health care professionals.
For American Pharmacists Month, see how recent instances of conflicting medical advice show the importance of pharmacists as trustworthy health care professionals.
A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.
This is the second generic version of mifepristone to be approved by the FDA.
Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.
Matthew D. Clark, PharmD, highlights a pharmacist-led program that improved opioid safety in cancer care despite regulatory exemptions.
Discover how pharmacists play a crucial role in the OUD treatment process with buprenorphine, enhancing patient care and recovery outcomes.
MD Anderson's opioid stewardship program enhances patient safety and care by monitoring opioid use, addressing discrepancies, and fostering multidisciplinary collaboration in cancer treatment.
The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).
FDA enhances oversight of drug ads using AI to ensure compliance, addressing risks and benefits in direct-to-consumer advertising.
Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.
Recent findings reveal that stereotactic radiation therapy (SABR) offers long-term survival outcomes comparable to surgery in patients with early non–small cell lung cancer (NSCLC).
Researchers uncover how apolipoprotein D (ApoD) increases influenza severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.
In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.
The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.
Gene therapy offers transformative potential in treating diseases like sickle cell and leukemia, highlighting pharmacists' crucial roles.
New research links oral bacteria and fungi to pancreatic cancer risk, suggesting oral microbiota as potential noninvasive biomarkers for early detection.
Gene therapy revolutionizes treatment in oncology, highlighting pharmacists' vital roles in patient care and long-term monitoring.
In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.
In this video, experts who attended the 2025 International Myeloma Society (IMS) Annual Meeting highlighted topics of interest as well as pivotal data.
A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.
Pharmacists play a vital role in Breast Cancer Awareness Month, enhancing screening access and patient support through education and community engagement.
A federal pricing pact with Pfizer and an executive order on pediatric cancer AI may reshape affordability and evidence pathways for pharmacists and patients.
Explore the booming online pharmacy market for vitamins and supplements, and discover how pharmacists can guide patients in this digital landscape.
BATURA demonstrated that albuterol/budesonide significantly reduced severe exacerbation risk reduction in patients with mild asthma.
Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.
Umoja Biopharma's UB-VV111 gains FDA fast track designation, revolutionizing CAR T-cell therapy for relapsed lymphoma and leukemia patients.
Cevostamab shows promise as a post-CAR T therapy for relapsed/refractory multiple myeloma, enhancing MRD-negative responses and improving patient outcomes.
AMT-130 demonstrates meaningful reductions in disease progression in the rare and chronic Huntington disease.
Recent trials reveal fam-trastuzumab deruxtecan-nxki's potential to transform treatment for patients with high-risk HER2-positive breast cancer, enhancing survival rates significantly.
Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).